The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

por Lu, Tingting, Huang, Yufan, Cai, Zhongjie, Lin, Wangchun, Chen, Xiaoxiao, Chen, Ruijia, Hu, Yingying
Publicado 2023

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

por You, Maojin, Zeng, Xiaoling, Zhang, Jinrong, Huang, Yufan, Zhang, Yalan, Cai, Zhongjie, Hu, Yingying
Publicado 2023

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

por He, Ying, Lin, Wangchun, Cai, Zhongjie, Huang, Yufan, You, Maojin, Lei, Meisheng, Chen, Ruijia
Publicado 2023

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma

por You, Maojin, Huang, Yufan, Cai, Zhongjie, Wu, Qingfeng, Zhu, Wei, He, Ying, Chen, Ruijia
Publicado 2022